Erlotinib can affect magnesium hemostasis, but its effect on systemic magnesium concentrations does not appear to be as good as that observed in antibody-based EGFR inhibitors, and the erlotinib-induced hypomagnesemia may be corrected by magnesia supplementation (13). Here, EGFR is linked to familial primary hypomagnesemia.